Peter van der Ark

The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study

Mark E. Schmidt, Michael R. Liebowitz, Murray B. Stein et al. · Neuropsychopharmacology · 2020 · 95 citations · Full text

The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder

Kasper Recourt, Peter de Boer, Rob Zuiker et al. · Translational Psychiatry · 2019 · 74 citations · Full text

Effect of intranasal esketamine on cognitive functioning in healthy participants: a randomized, double-blind, placebo-controlled study

Randall L. Morrison, Maggie Fedgchin, Jaskaran Singh et al. · Psychopharmacology · 2018 · 70 citations · Full text

The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia

Sander Brooks, Gabriël E. Jacobs, Peter de Boer et al. · Journal of Psychopharmacology · 2019 · 69 citations

Preliminary evidence of anxiolytic effects of the CRF₁ receptor antagonist R317573 in the 7.5% CO₂ proof-of-concept experimental model of human anxiety

Jayne Bailey, Andreas Papadopoulos, Alison Diaper et al. · Journal of Psychopharmacology · 2011 · 55 citations

Affective Neuroscience, Receptor Antagonist, Psychopharmacology +22